{{'Search' | translate}}
 

Glass Büchner filter funnel

Company: Merck
Catalog#: XX1014700
Bio-protocol()
Company-protocol()
Other protocol()

Polyamine Transport Assay Using Reconstituted Yeast Membranes
Author:
Date:
2021-01-20
[Abstract]  

ATP13A2/PARK9 is a late endo-/lysosomal P5B transport ATPase that is associated with several neurodegenerative disorders. We recently characterized ATP13A2 as a lysosomal polyamine exporter, which sheds light on the molecular identity of the unknown mammalian polyamine transport system. Here, we describe step by step a protocol to measure radiolabeled polyamine transport in reconstituted vesicles from yeast cells overexpressing human ATP13A2. This protocol was developed as part of our recent publication (van Veen et al., 2020) and will be useful for characterizing the transport function of other putative polyamine transporters, such as isoforms of the P5B transport ATPases.

[摘要]  [摘要] ATP13A2 / PARK9是一种晚期内/溶酶体P5B转运ATPase,与多种神经退行性疾病有关。我们最近将ATP13A2表征为溶酶体多胺出口者,这为未知的哺乳动物多胺转运系统的分子身份提供了线索。在这里,我们逐步描述了从过量表达人ATP13A2的酵母细胞中测量重组囊泡中放射性标记的多胺转运的方案。该方案是我们最新出版物的一部分(van Veen等,2020),将有助于表征其他假定的多胺转运蛋白的转运功能,例如P5B转运ATPase的同工型。


[背景] ATP13A2 / PARK9编码一种普遍表达的晚期内-/溶酶体膜蛋白,与一系列神经退行性疾病有关,例如早发性帕金森氏病(Di Fonzo等,2007 ;Lin等,2008)和Kufor -Rakeb综合征(伴痴呆的早期帕金森病)(Ramirez等,2006 ;Park等,2011)。ATP13A2属于P型转运ATPase ,是一类活性转运蛋白,由于ATP水解而暂时形成磷酸中间产物(Kuhlbrandt ,2004年)。ATP13A2是P5亚家族的成员,该家族已在20多年前通过基因组测序鉴定出来(Axelsen和Palmgren ...

Heterologous Expression and Purification of the CRISPR-Cas12a/Cpf1 Protein
Author:
Date:
2018-05-05
[Abstract]  This protocol provides step by step instructions (Figure 1) for heterologous expression of Francisella novicida Cas12a (previously known as Cpf1) in Escherichia coli. It additionally includes a protocol for high-purity purification and briefly describes how activity assays can be performed. These protocols can also be used for purification of other Cas12a homologs and the purified proteins can be used for subsequent genome editing experiments.


Figure 1. Timeline of activities for the heterologous expression and purification of Francisella novicida Cas12a (FnCas12a) from Escherichia coli
[摘要]  该协议提供了分步说明(图1),用于在大肠杆菌中异源表达新西兰弗朗西斯菌弗朗西丝菌Cas12a(以前称为Cpf1)。 它还包括一个高纯度纯化方案,并简要介绍如何进行活性测定。 这些方案也可以用于其他Cas12a同系物的纯化,并且纯化的蛋白质可以用于随后的基因组编辑实验。

“”src
图1.从大肠杆菌 异源表达和纯化<弗朗西斯弗朗西丝菌 Cas12a(FnCas12a)的活动时间表

【背景】原核CRISPR-Cas免疫系统通过使用CRISPR RNA(crRNA)作为外源DNA或RNA的序列特异性靶向的指导来提供针对病毒和质粒的保护(van der Oost等人,2014; Marraffini ,2015)。 1类CRISPR-Cas系统(包含I型,III型和IV型)通常形成多亚基蛋白-cRNA效应复合物,而2类系统(包含II型,V型和VI型)依赖于单个crRNA-引导的效应物核酸酶用于目标干扰(Mohanraju et al。 2016年)。

...

Comments